<DOC>
	<DOCNO>NCT00685178</DOCNO>
	<brief_summary>This outpatient clinical trial topiramate address cocaine dependence reduction cocaine associate behavior opiate dependent drug user maintain methadone treatment . The study aim answer whether topiramate 1. safe acceptable methadone patient 2. reduces cocaine use 3. help collateral problem alcohol abuse , tobacco dependence , anxiety , PTSD and/or pain symptom . The study also evaluate topiramate effect neuro-cognitive performance .</brief_summary>
	<brief_title>Clinical Trial Topiramate Cocaine Addiction</brief_title>
	<detailed_description>This outpatient clinical trial topiramate treatment cocaine dependence reduction cocaine-associated HIV risk behavior . Topiramate high current interest regard , identify NIDA leadership among small number test candidate provide `` positive signal '' warrant clinical investigation ( Vocci , 2005 ) . Topiramate market antiepileptic enhances GABAergic system antagonize glutamatergic system , new target search anti-cocaine treatment . A publish pilot trial support topiramate 's efficacy , especially intrigue potentially beneficial disorder prevalent among drug user , mood , anxiety , panic disorder , PTSD , pain cognitive dysfunction , may contribute drug use . Design/Methods : This phase II , double-blind randomize ( stratify ) 4 group , 2x2 design , evaluate topiramate versus placebo two level cocaine-abstinence motivation -- cocaine-abstinence-contingent versus non-contingent voucher incentive . Conduct methadone maintenance context ensure adequate retention adherence , participant dually dependent opioids cocaine . The target topiramate stabilization dose 300 mg/day ( 150 mg b.i.d . ) , one dose per day observe clinic . The voucher-incentive manipulation provide valuable information role motivation modulate medication effect ; also provide positive control condition document sensitivity study method detect therapeutic benefit . Enrollment 300 patient ( 240 completers , 60/group ) . Participation 33 week - Baseline/Placebo-Run-in ( 5 week ) , Randomized Medication Treatment ( 20 week , induction , stable dosing , taper ) , Randomized Voucher Treatment ( 12 week , embedded Medication period ) , Therapeutic Disposition ( 8 week ) . Data analysis focus 8-week period stable dose concurrent voucher . The primary outcome variable day abstinent cocaine , determine combination self-report objective confirmation quantitative urinalysis toxicology cocaine metabolite level application `` Preston '' rule determine abstinence . Secondary outcome variable measure adverse behavior symptom commonly co-occurring cocaine abuser ( alcohol abuse , tobacco use , depression , anxiety , PTSD , pain , neuro-cognitive psychomotor performance dysfunction ) may contribute drug use and/or detrimental effect . Significance : This randomize control clinical trial provide valuable information action therapeutic effectiveness promise candidate anti-cocaine pharmacotherapy topiramate , condition , correlate , modulators observe effectiveness . It also provide valuable methodological information contribute continue evolution clinical trial method evaluate potential drug abuse treatment medication .</detailed_description>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>18 55 year old active opioid cocaine dependence seek treatment cocaine opioid dependence eligible methadone maintenance per state federal regulation able willing provide urine sample thrice week willing answer questionnaire weekly basis willing provide breath sample presence alcohol thrice weekly fluent English language allergy sulfonamide drug diabetes , respiratory insufficiency , renal tubular acidosis , renal insufficiency , heart failure , liver insufficiency , chronic diarrhea , chronic disease predispose risk acidosis history nephrolithiasis HIV positive individual meet AIDS criterion CDC criterion take antiretroviral medication serious psychiatric illness ( psychosis , dementia ) glaucoma family history glaucoma prostate hyperplasia , shy bladder , irritable bladder , difficulty provide urine sample demand female participant : pregnant , lactating , unwilling use effective method contraception use antiepileptic agent benzodiazepine dependence latex allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>addiction</keyword>
	<keyword>drug dependence</keyword>
	<keyword>stimulant</keyword>
</DOC>